Ad
CATB - Catabasis Pharmaceuticals Stock Trading
About | Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)
Not available
Quote | Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)
| Last: | $8.54 |
|---|---|
| Change Percent: | -6.97% |
| Open: | $9.21 |
| Close: | $8.54 |
| High: | $9.21 |
| Low: | $8.46 |
| Volume: | 98,765 |
| Last Trade Date Time: | 09/08/2021 04:56:30 pm |
News | Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)
-
Catabasis Pharmaceuticals (CATB -3.0%) announces its new name, Astria Therapeutics. The name Astria originates from the Greek word for star, reflecting the company’s commitment to having patients serve as guiding stars. Astria expects to begin trading under the new ticker symbol '...
-
-- Astria Reflects Company’s Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 -- Cataba...
Message Board Posts | Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)
| Subject | By | Source | When |
|---|---|---|---|
| ATXS new ticker. | harr449 | investorshub | 09/09/2021 1:07:41 PM |
| Cause it ain't gonna stay this high. | ErnieBilco | investorshub | 08/21/2021 2:03:49 AM |
| UNHINGED DUMPING | Disquisition | investorshub | 08/20/2021 7:48:19 PM |
| lets see if this can hold today and | Tzr250rg | investorshub | 07/21/2021 1:39:14 PM |
| why the decline with Black rock, Perceptive, Xontogeny, | Tzr250rg | investorshub | 07/16/2021 2:41:04 PM |
News, Short Squeeze, Breakout and More Instantly...
Catabasis Pharmaceuticals Inc. Company Name:
CATB Stock Symbol:
NASDAQ Market:
Catabasis Pharmaceuticals Inc. Website:
Ad
-
-- Astria Reflects Company’s Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 -- Cataba...
-
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “We are focused on advancing the development of our lead program, QLS-215, as a differe...